Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention

S Mirzaei, MDA Paskeh, E Okina, MH Gholami… - Journal of Experimental …, 2022 - Springer
Background One of the most malignant tumors in men is prostate cancer that is still incurable
due to its heterogenous and progressive natures. Genetic and epigenetic changes play …

Metabolic adaptations in prostate cancer

M Pujana-Vaquerizo, L Bozal-Basterra… - British Journal of …, 2024 - nature.com
Prostate cancer is one of the most commonly diagnosed cancers in men and is a major
cause of cancer-related deaths worldwide. Among the molecular processes that contribute …

Targeting microglial metabolic rewiring synergizes with immune-checkpoint blockade therapy for glioblastoma

Z Ye, X Ai, K Yang, Z Yang, F Fei, X Liao, Z Qiu… - Cancer discovery, 2023 - AACR
Glioblastoma (GBM) constitutes the most lethal primary brain tumor for which
immunotherapy has provided limited benefit. The unique brain immune landscape is …

Dysregulation of cholesterol metabolism in cancer progression

X Liu, M Lv, W Zhang, Q Zhan - Oncogene, 2023 - nature.com
Cholesterol homeostasis has been implicated in the regulation of cellular and body
metabolism. Hence, deregulated cholesterol homeostasis leads to the development of many …

Cholesterol metabolism in cancer and cell death

F Chen, Y Lu, J Lin, R Kang, J Liu - Antioxidants & Redox Signaling, 2023 - liebertpub.com
Significance: Cholesterol is a type of lipid that plays a crucial role in building and
maintaining cell membranes, producing certain hormones, and aiding in digestion. The two …

Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects

M Hashemi, S Mirzaei, M Barati, ES Hejazi… - Life sciences, 2022 - Elsevier
Urological cancers include bladder, prostate and renal cancers that can cause death in
males and females. Patients with urological cancers are mainly diagnosed at an advanced …

Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer

K Gao, X Li, J Ni, B Wu, J Guo, R Zhang, G Wu - Cancer Letters, 2023 - Elsevier
Enzalutamide (Enz) is a next-generation androgen receptor (AR) antagonist used to treat
castration-resistant prostate cancer (CRPC). Unfortunately, the relapsing nature of CRPC …

Squalene epoxidase metabolic dependency is a targetable vulnerability in castration-resistant prostate cancer

X Shangguan, Z Ma, M Yu, J Ding, W Xue, J Qi - Cancer Research, 2022 - AACR
Considering the dismal prognosis of castration-resistant prostate cancer (CRPC), it is critical
to identify novel therapeutic targets in this disease. Malignant cells have metabolic …

Key regulatory miRNAs in lipid homeostasis: Implications for cardiometabolic diseases and development of novel therapeutics

AA Khan, V Gupta, NR Mahapatra - Drug Discovery Today, 2022 - Elsevier
Dysregulation of lipid metabolism is associated with cardiovascular/metabolic diseases,
including atherosclerosis, liver diseases and type 2 diabetes mellitus (T2DM). Several …

Metabolic changes during prostate cancer development and progression

AMK Beier, M Puhr, MB Stope, C Thomas… - Journal of cancer …, 2023 - Springer
Metabolic reprogramming has been recognised as a hallmark in solid tumours. Malignant
modification of the tumour's bioenergetics provides energy for tumour growth and …